Dr. Matthew Herrmann, M.D.
Rheumatology (Rheumatology Physician)
4550 E Bell Rd Ste 170
Phoenix, AZ 85032
Who else practices at this address →
Maricopa County includes primary care (13% of residents) and dental (0% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Cincinnati College of Medicine (2015)
- Years since graduation
- 11
- In the NPI registry since
- 2015
- Medicare patients seen, 2024
- 748
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Medical school: University of Cincinnati College of Medicine
- 2015Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
AZ license 59895 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Arizona Arthritis and Rheumatology Associates P C (65 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 748
- Services billed
- 205,456
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, romosozumab-aqqg, 1 mg | 25,830 | 30 |
| Injection, denosumab, 1 mg | 4,680 | 58 |
| Insertion of needle into vein for collection of blood sample | 365 | 235 |
| Established patient office or other outpatient visit, 30-39 minutes | 337 | 189 |
| Blood test, comprehensive group of blood chemicals | 295 | 197 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 248 | 173 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 213 | 88 |
| Measurement c-reactive protein for detection of infection or inflammation | 184 | 116 |
| New patient office or other outpatient visit, 45-59 minutes | 184 | 184 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 163 | 26 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 158 payments worth $3,397 in total to this clinician.
| AbbVie Inc. | $960 |
|---|---|
| Amgen Inc. | $548 |
| UCB, Inc. | $459 |
| Genzyme Corporation | $301 |
| Mallinckrodt Hospital Products Inc. | $200 |
| Pfizer Inc. | $156 |
| Novartis Pharmaceuticals Corporation | $147 |
| E.r. Squibb & Sons, L.l.c. | $116 |
| Food and Beverage | $3,297 |
|---|---|
| Education | $99.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Mallinckrodt Hospital Products Inc. Dec 1, 2025 | Education ACTHAR · IMMUNOLOGY · in-kind Company’s descriptionRelevant medical textbook or clinical reprint | $99.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $348,018 in research payments for these studies, mostly to the institutions running them.
- A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgren's Syndrome
Amgen Inc. - Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
Eli Lilly and Company · Completed · NCT06588296 - A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
UCB SA · Recruiting · NCT06617325 - A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease
Janssen Research & Development, LLC - A phase 2A, single-arm study to investigate the efficacy and safety of LY3541860 in adult participants with moderately-to-severely active rheumatoid arthritis
Eli Lilly and Company - A phase 4, prospective, open-label, single-arm study to assess the effectiveness of tirzepatide after initiation of ixekizumab in adult participants with active psoriatic arthritis and overweight or obesity in clini…
Eli Lilly and Company - The evaluation of use of belimumab in routine care settings in lupus n
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.